Oncolytic virus treatment differentially affects the CD56dim and CD56bright NK cell subsets in vivo and regulates a spectrum of human NK cell activity. - Wantoch M; Wilson EB; Droop AP; Phillips SL; Coffey M; El-Sherbiny YM; Holmes TD; Melcher AA; Wetherill LF; Cook GP (Immunology, 2022)